BACKGROUND: Poor glycemic control is associated with increased risk of cardiovascular disease (CVD) in type 1 diabetes mellitus (T1DM); however, little is known about mechanisms specific to T1DM. In T1DM, myocardial injury can induce persistent cardiac autoimmunity. Chronic hyperglycemia causes myocardial injury, raising the possibility that hyperglycemia-induced cardiac autoimmunity could contribute to long-term CVD complications in T1DM.
D
espite improvements in cardiovascular disease (CVD) outcomes in type 1 diabetes mellitus (T1DM), 1 patients with poor glycemic control experience a >10-fold increased risk of morbidity and mortality from CVD compared with the general population. 2, 3 Patients with T1DM generally do not have the same CVD risk factors as those with type 2 diabetes mellitus (T2DM), [2] [3] [4] [5] and conventional CVD risk factors explain less than half of the increased CVD risk in T1DM. 4, 6 Despite evidence that lowering hemoglobin A 1c (HbA 1c ) to near-normal levels reduces the development of diabetes complications in T1DM, 7, 8 25% to 30% of patients currently have poor glycemic control. 3, 9 Without knowledge of T1DM-specific mechanisms for CVD, it is difficult to identify which patients might benefit from more aggressive cardioprotective measures 10 or to design T1DM-targeted CVD therapies.
A large body of evidence implicates inflammation, including dysfunctional adaptive immunity, in the pathogenesis of atherosclerosis. [11] [12] [13] T1DM is an autoimmune disorder that is thought to be triggered by dysregulated (overreactive) adaptive immune responses to pancreatic islet injury.
14 Although this disease process is T cell-mediated, 15, 16 the presence of islet autoantibodies (AAbs), particularly ≥2 different islet AAb types, is strongly predictive of progression to clinical T1DM. [17] [18] [19] Recently, our group has shown that myocardial infarction (MI) in T1DM mouse models and patients with T1DM, but not post-MI control mice and patients with T2DM, induces sustained proinflammatory CD4 + T-cell and AAb responses against α-cardiac myosin heavy chain (MYH6), a major autoantigen in myocarditis. 20 Chronic hyperglycemia may also cause cardiomyocyte injury. [21] [22] [23] [24] We hypothesized that chronic hyperglycemia would induce cardiac autoimmunity in T1DM and that these dysfunctional immune responses would be associated with an inflammatory state, thereby increasing CVD risk. The landmark DCCT (Diabetes Control and Complications Trial) provided a unique opportunity to test these hypotheses because participants were devoid of CVD complications at baseline, and the 2 diabetes treatment groups (intensive and conventional) achieved markedly different mean HbA 1c levels during the trial. Furthermore, CVD outcomes were available from the post-DCCT EDIC observational study (Epidemiology of Diabetes Interventions and Complications), with a 30-year follow-up. 8, 25 
METHODS
The data, analytical methods, and study materials will be/ have been made available to other researchers through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository 26 for purposes of reproducing the results or replicating the procedures, with biosamples subject to approval by the NIDDK.
Patients and Experimental Design
We analyzed samples from participants with T1DM in the DCCT study and from 3 additional well-characterized groups: a T2DM cohort without clinical CVD, 27 a chronic Chagas cardiomyopathy cohort, and a healthy control group. 28 The T2DM cohort was included to examine the effect of hyperglycemia in the absence of an autoimmune-prone T1DM background, whereas the Chagas cardiomyopathy cohort represented a positive control because this disease is believed to represent a form of chronic myocarditis driven by autoimmunity against cardiac myosin.
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Type 1 Diabetes Mellitus
The DCCT study cohort has been described in detail. 7 In brief, between 1983 and 1993, 1441 patients (age, 13-39 years) with T1DM were randomly assigned to conventional versus intensive diabetes therapy, achieving mean HbA 1c levels of 9.1% and 7.2%, respectively. At the baseline visit (1983) (1984) (1985) (1986) (1987) (1988) (1989) , all participants were free of a history of clinical CVD, hypertension, and hypercholesterolemia. The primary prevention cohort had a short duration of diabetes mellitus (1-5 years) and was devoid of retinopathy or microalbuminuria at baseline. After DCCT, the cohort was followed up annually in the observational EDIC study (1994 to present). 30 The mean HbA 1c during EDIC has been 8.0% in both groups. 31 
Clinical Perspective
What Is New?
• First demonstration that in patients with type 1 diabetes mellitus, poor glycemic control is associated with cardiac autoimmunity, as evidenced by the presence of multiple (≥2) cardiac autoantibody types.
• Positivity for ≥2 cardiac autoantibodies was associated with increased risk of both cardiovascular disease (CVD) events and coronary artery calcification decades later.
• Positivity for ≥2 autoantibodies also identified patients with type 1 diabetes mellitus with elevated high-sensitivity C-reactive protein, suggesting that cardiac autoimmunity is associated with an inflammatory state, which may link autoantibodies to CVD outcomes. • Poor glycemic control was not associated with cardiac autoimmunity in type 2 diabetes mellitus, suggesting a novel CVD pathway specific to type 1 diabetes mellitus.
What Are the Clinical Implications?
• Further validation of cardiac autoantibodies as predictive biomarkers of CVD events in type 1 diabetes mellitus could aid in the identification of patients at highest risk for future CVD outcomes. It may also ultimately lead to new ways to prevent CVD. 
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The present studies include follow-up through December 31, 2013 (EDIC year 20) . 25 On the basis of a preliminary cross-sectional study suggesting a relationship between expression of cardiac AAbs and glycemic control in young adults with T1DM with HbA 1c ≤7.0% and ≥9.0% ( Figure I in the online-only Data Supplement), we estimated that ≥3 longitudinal samples from at least 144 patients in the DCCT primary prevention cohort (72 in each HbA 1c group) would be required to have 80% power at a type I error rate of 0.05 to detect a 20% relative between-group difference in the proportion of patients testing positive for cardiac AAbs over time. We requested longitudinal samples from conventionally treated participants with mean HbA 1c levels (defined as the average of all available longitudinal HbA 1c data up to the last visit of DCCT) ≥9.0% and contemporaneously obtained longitudinal samples from intensively treated patients with mean HbA 1c ≤7.0%, matched for age, sex, and T1DM duration, from the NIDDK Repository ( Figure II in the online-only Data Supplement). We excluded patients who developed CVD events (defined as nonfatal MI, stroke, cardiovascular death, confirmed angina, congestive heart failure, and coronary artery revascularization) 25 and renal disease (defined as albumin excretion rate ≥300 mg/24 h or estimated glomerular filtration rate <60 mL·min 
Type 2 Diabetes Mellitus
We obtained serum samples from a T2DM cohort without clinical CVD, 27 1 group with HbA 1c ≥9.0% (n=70) and the other with HbA 1c ≤7.0% (n=140; Table I in the online-only Data Supplement).
Chronic Chagas Cardiomyopathy
Serum samples were obtained from the Brazilian Consortium of Genetics in Chagas Cardiomyopathy cohort (mean ejection fraction, 32%; New York Heart Association functional class II or greater, 88%; Table II in the online-only Data Supplement).
Healthy Control Subjects
Serum samples from 115 healthy control subjects 28 were analyzed as a reference to determine the cutoffs for AAb positivity.
HLA Genotyping
HLA genotyping was performed as described.
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Detection of Cardiac Autoimmunity
On the basis of previous studies showing that the use of a panel of cardiac AAbs provided more sensitivity and specificity for the detection of myocarditis than a single AAb, 28 we measured AAbs to the following antigens: full-length (FL)-MYH6, FL-β-cardiac myosin heavy chain (FL-MYH7), cardiac troponin I (cTnI), S1 "head" fragment of MYH6 (S1-MYH6), and S2 fragment of MYH6 (S2-MYH6). 28 Cardiac AAbs were quantitated with fluid-phase radioimmunoprecipitation assays with in vitro transcribed and translated cDNAs encoding FL-MYH6, FL-MYH7, S1-MYH6, S2-MYH6, and cTnI, as described 28 with minor modifications (Methods in the online-only Data Supplement). The AAb index was defined as follows: (counts per minute [CPM] in the unknown sample−CPM in the negative control standard)/ (CPM in the positive standard−CPM in the negative standard)×100. These AAb assays were reproducible with the following intra-assay and interassay coefficients of variation (%): FL-MYH6, 3.0 and 6.3; S1-MYH6, 5.6 and 12.0; S2-MYH6, 8.3 and 11.9; FL-MYH7, 6.8 and 13.4; and cTnI, 4.4 and 10.0, respectively, within the range of other AAb assays used in multicenter clinical trials.
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CVD Outcomes
The cardiovascular outcomes were defined as a composite of nonfatal MI, stroke, CVD death, congestive heart failure, or coronary artery bypass grafting that occurred between the end of DCCT and EDIC year 20. 25 Furthermore, we examined coronary artery calcification (CAC), measured once during EDIC years 7 to 9.
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Statistical Analyses
Clinical characteristics were compared with the Student t test or Wilcoxon test for continuous variables and the χ 2 test for categorical variables. When multiple between-group comparisons were made, ANOVA or the Kruskal-Wallis test was used, and when appropriate, pairwise differences of interest were assessed with the Student t test. The cardiac AAb levels and their changes across time between the 2 DCCT HbA 1c groups were compared with linear mixed models. These repeatedmeasures models included the group assignment, the year of DCCT treatment, and their interaction over time. Logistic regression was used to investigate the relationship between AAb status and odds of having subsequent CAC or a CVD event (odds ratio and 95% CI). Cox proportional hazards regression was used to assess the risk of incident CVD events relative to the number of cardiac AAbs (hazard ratio and 95% CI), and the Kaplan-Meier method and log-rank test were used to evaluate time to CVD events. Multivariable models examined the independent association of cardiac AAbs, adjusted for age at visit before the CAC measurement, sex, smoking status, and hypertension at the end of the DCCT study, with CAC risk. To examine the relationship between the type or number of AAbs during DCCT and high-sensitivity C-reactive protein (hsCRP) levels, the latter were log-transformed and analyzed by means of linear regression models not including (unadjusted analyses) or including (adjusted analyses) sex as an additional covariate. To facilitate interpretation, hsCRP data are presented as medians (first, third quartiles) in the original scale. For all inferential analyses, estimates of effects are reported with 95% CIs and 2-sided P values. A 2-sided value of P<0.05 was nominally significant. In Figure 1 , we corrected for multiple testing using the Benjamini-Hochberg procedure to control the false discovery rate at 5%. 35 All statistical analyses were conducted with SAS version 9.4. 
Ethical Considerations
The DCCT/EDIC biosamples and data sets obtained from the NIDDK Repository were deemed not to constitute human subject research. The other studies were approved by Joslin Committee on Human Studies (Nos. 99-20 and 04-34) and University of Sao Paulo Medical School (No. 0398/04). All participants gave written informed consent.
RESULTS
Characteristics of the DCCT Patients
The characteristics of the patients with T1DM at baseline and at the end of DCCT are summarized in Table 1 . The HbA 1c ≥9.0% group was slightly younger than the . Number below Masked_ID is the DCCT/EDIC masked identifier number. A 1c indicates glycosylated hemoglobin level; CABG, coronary artery bypass graft; cTnI, cardiac troponin I; FL-MYH6, full-length α-cardiac myosin heavy chain; FL-MYH7, full-length β-cardiac myosin heavy chain; MI, nonfatal myocardial infarction; NA, not applicable; S1-MYH6, S1 fragment of α-cardiac myosin heavy chain; and S2-MYH6, S2 fragment of α-cardiac myosin heavy chain. 
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001).
Compared with the HbA 1c ≤7.0% group, the body mass index was slightly greater in the HbA 1c ≥9.0% group at baseline but not at the end of DCCT. The groups were otherwise similar in CVD risk factors at the beginning and end of DCCT. As prespecified in our study design, none of the patients had CVD or renal disease at the end of DCCT. Consistent with the DCCT study design, none of the participants had microalbuminuria, dyslipidemia, or hypertension at baseline, and none were on statins or agents that target the renin-angiotensin axis during DCCT.
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Class II HLA Genotype and Islet Autoantibody Status
In view of the strong association between particular class II HLA alleles and autoimmune disease susceptibility, high-resolution HLA typing of DRB1, DQA1, and DQB1 alleles was performed. These studies (Table III in the online-only Data Supplement) showed that the 2 HbA 1c groups carried similar frequencies of HLA class II genotypes. Consistent with these findings, the prevalence of AAbs to glutamic acid decarboxylase 65 and protein tyrosine phosphatase IA-2A, measured within 4 years of T1DM diagnosis, 36 was similar in the 2 groups. Taken together, these results indicate that the 2 groups were genetically and immunologically similar.
Prevalence and Profiles of Cardiac AAbs
As shown in Figure 1 , patients with T1DM with HbA 1c ≥9.0% showed substantially higher mean levels of AAbs to S1-MYH6, S2-MYH6, and cTnI compared with the HbA 1c ≤7.0% group during DCCT (P<0.001). There was also a suggestive but nonsignificant difference in AAb levels to FL-MYH6 and FL-MYH7 between the 2 DCCT HbA 1c groups (P=0.06 for both AAbs). In contrast, there was no relationship between glycemic control and cardiac AAb expression in patients with T2DM.
The most frequently detected AAb type in the T1DM DCCT HbA 1c >9.0% group was S1-MYH6, with positivity in 27% of patients (22 of 83), which was similar in prevalence to Chagas cardiomyopathy, with 31% patients (16 of 51; P=0.54) positive, but distinct from the HbA 1c <7.0% group in which none of the patients were positive. The second most prevalent AAb type was S2-MYH6, which was positive in 22% (18 of 83) of patients with HbA 1c ≥9.0%, identical to Chagas cardiomyopathy with 22% (11 of 51 patients) positive, but distinct from the HbA 1c ≤7.0% group in which only a single patient (1%) was positive (P<0.001).
As shown in Figure 2 and Table IV in the online-only Data Supplement, in the DCCT HbA 1c ≥9.0% group, 46% (38 of 83) patients tested positive for ≥1 cardiac AAbs, 22% (18 of 83) tested positive for ≥2 AAbs, and 11% (9 of 83) tested positive for ≥3 AAbs, with a prevalence similar to that of patients with Chagas cardiomyopathy. In contrast, in the DCCT HbA 1c ≤7.0% group, only 2% (2 of 83) had ≥1 AAbs and 1% (1 of 83) had ≥2 AAbs, with no patients testing positive for ≥3 AAbs. There was no relationship between glycemic control and the number of AAbs in patients with T2DM, with 11 of 140 (8%) versus 5 of 70 (7%) positive in the HbA 1c ≤7.0% and ≥9.0% groups, respectively (P=0.85). In addition, none of the patients with T2DM or healthy control subjects tested positive for ≥2 AAbs.
Temporal Dynamics of Cardiac AAb Expression
As shown in Figure 3A and Figure IV in the online-only Data Supplement, the trajectory of cardiac myosin AAb levels over time (from DCCT years 1-8) was markedly different in the 2 HbA 1c groups (P<0.001). The most striking findings were for S1-MYH6, with modest differences between both groups in AAb titers at year 1 of DCCT (0.222±0.037 versus 0.206±0.064; P=0.04). By DCCT year 2, the groups diverged, with a progressive increase in mean S1-MYH6 titers in the HbA 1c ≥9.0% group over time and a progressive decrease in AAb titers in the HbA 1c ≤7.0% group over time up to DCCT year 8 (0.329±0.038 versus 0.131±0.035 in the HbA 1c ≥9.0% and ≤7.0% groups, respectively; P<0.001). These patterns correlated with evidence of AAb seroconversion in individuals in the HbA 1c ≥9.0% group and, conversely, disappearance of AAb positivity in the HbA 1c ≤7.0% group (Figure IVA in the online-only Data Supplement). In contrast, no significant interactions were observed for the HbA 1c group and DCCT year with cTnI AAb levels over time (P=0.26; Figure  4B in the online-only Data Supplement).
Cardiac AAbs and Future CVD Events
Patients with the highest titers of cardiac AAbs during DCCT were subsequently found to develop CVD events during EDIC, up to 26 years after the first positive AAb test (Figures 1 and 3A) . Furthermore, among the AAbpositive patients who developed CVD events (4 of 6 subjects), all tested positive for ≥2 AAbs (Figure 1 and (Figure 1 ) and the only patient to experience a fatal CVD event. The insets in Figure 3A also underscore the relatively high cardiac AAb titers during DCCT in patients who subsequently developed CVD events, including Masked_ID 635, who was not AAb-positive but, in the single sample available for testing from DCCT year 2, was already borderline FL-MYH6 AAb-positive. Because the primary prevention cohort was relatively healthy and young at baseline and patients who developed renal disease or CVD were excluded from this study ( Figure  II in the online-only Data Supplement), the total number of CVD events was relatively low (Table V in the online-only Data Supplement). However, among the 6 patients who Table 2 ). A, Interaction between the mean AAb level; S1 fragment of α-cardiac myosin heavy chain (S1-MYH6; top), S2 fragment of α-cardiac myosin heavy chain (S2-MYH6; middle), or full-length α-cardiac myosin heavy chain (FL-MYH6; bottom); HbA 1c group (≥9.0% or ≤7.0%); and year of DCCT intervention treatment. All relationships were significant (P<0.001). Because only 2 subjects had samples available from DCCT year 0 (ie, at DCCT baseline), year 0 is not included. The numbers of samples analyzed in each HbA 1c group per DCCT year are as indicated. Insets show the patients who developed cardiovascular disease events (as shown in Figure 1) Table 2 ) and a significantly lower cumulative CVD event-free survival rate compared with subjects with ≤1 AAbs (P<0.001; Figure  V in the online-only Data Supplement).
Cardiac AAbs as Predictors of Subclinical CVD
We next analyzed whether the specificity or number of cardiac AAbs during DCCT was also associated with a greater risk of subsequent CAC, a marker of subclinical coronary atherosclerosis, measured in EDIC years 7 to 9. 34 As shown in Table IV Univariable analyses were conducted with logistic regression. Multivariable analyses were adjusted for age at the visit before the CAC measurement, sex, smoking status, and hypertension at the end of DCCT. No significant effect of hyperlipidemia at the end of DCCT or smoking and hypertension at the visit before the CAC measurement during the EDIC follow-up study (Epidemiology of Diabetes Interventions and Complications) was observed. AAb indicates autoantibody; CAC, coronary artery calcification; DCCT, Diabetes Control and Complications Trial; FL-MYH6, full-length α-cardiac myosin heavy chain; and S2-MYH6, S2 fragment of cardiac α-myosin heavy chain.
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Using a multivariable model adjusted for age at the visit before CAC measurement, sex, smoking status, and hypertension at the end of DCCT, 34 
Cardiac AAbs and Subsequent Levels of hsCRP
We further investigated whether specificity or the number of cardiac AAbs during DCCT was also associated with levels of the inflammatory marker hsCRP, measured during EDIC years 4 to 6. 37, 38 As shown in Figure 4 As shown in Table VI in the online-only Data Supplement, positivity for S2-MYH6 AAb during DCCT was associated with a 2.0-fold increased level of hsCRP compared with patients who were negative for this AAb type (95% CI, 1.1-3.8; P=0.03). Positivity for FL-MYH6 AAb during DCCT was associated with 2.1-fold greater hsCRP levels compared with patients who were FL-MYH6 AAbnegative (95% CI, 1.9-2.4; P=0.03) . In analysis of hsCRP adjusted for sex, patients who were positive for S2-MYH6 AAb had 2.1-fold higher hsCRP level compared with patients who were negative for this AAb type (95% CI, 1.1-3.9; P=0.02), whereas patients who were positive for FL-MYH6 AAb had 2.3-fold greater levels of hsCRP than those who were FL-MYH6 AAb-negative (95% CI, 1.2-4.3; P=0.02) . In this adjusted model, positivity for ≥2 AAb was associated with a 2.7-fold increased level of hsCRP compared with patients who were positive for only 1 AAb or who were AAb-negative (95% CI, 1.5-4.7, P=0.001). Further adjustment of these analyses by age, mean HbA 1c levels during DCCT, smoking, hypertension, and hyperlipidemia at the end of DCCT did not significantly affect the relationship between the type or number of AAbs and hsCRP levels.
DISCUSSION
In this first evaluation of the relationship among glycemic control, cardiac autoimmunity, and CVD complications in patients with T1DM, we demonstrate the following findings. First, in patients with T1DM, poor glycemic control alone, in the absence of clinical CVD, renal disease, or other diabetes-related comorbidities, is associated with the development of cardiac autoimmunity. Second, our data suggest that the risk of both accelerated atherosclerosis (as measured by CAC) and CVD events is higher in patients with T1DM with cardiac autoimmunity, as evidenced by positivity for ≥2 cardiac AAbs, which developed decades in advance of these CVD complications. Third, positivity for ≥2 cardiac AAbs also identified patients who subsequently showed elevated hsCRP levels, suggesting that cardiac autoimmunity could be associated with an inflammatory state, which may link AAbs to CVD outcomes. Relatively little is known about the mechanisms of CVD specific to T1DM except for the substantial risk conferred by diabetic kidney disease. 6, 39 Although many studies have established hyperglycemia as a key mediator of CVD events and CVD-related mortality in T1DM 2, 3, 8, 40 and numerous metabolic factors related to diabetes mellitus have been implicated, 4 none have been unique ORIGINAL RESEARCH ARTICLE to T1DM. Our findings suggest a novel CVD pathway that is specific to T1DM. The impact of glycemic control on cardiac AAb expression was demonstrated in our study by several findings: (1) the mean AAb levels during DCCT; (2) the significant relationship between the level of cardiac myosin AAbs, group (HbA 1c ≥9.0% versus ≤7.0%), and time (DCCT year), with the AAb levels increasing over time in the HbA 1c ≥9.0% group but decreasing over time in the HbA 1c ≤7.0% group; (3) the number of cardiac AAbs produced; and (4) the antigenic specificities of the AAbs. An unexpected finding was the similar cardiac AAb expression profiles in the DCCT HbA 1c ≥9.0% group, who were young, generally healthy, and devoid of clinical CVD when the AAbs first appeared, and the patients with heart failure caused by Chagas cardiomyopathy, which is a form of chronic myocarditis, pointing to possible autoimmune commonalities in the pathogenesis of these seemingly unrelated conditions. Of note, the presence of cardiac autoimmunity in T1DM could not be simply explained by the metabolic effects of hyperglycemia given the lack of a relationship between glycemic control and AAb expression in patients with T2DM.
Our longitudinal studies in the low HbA 1c (≤7.0%) group are noteworthy in indicating that cardiac autoimmunity in its earliest stages can be transient when the trigger (here, hyperglycemia) is removed. This contrasts with the situation of chronic myocarditis associated with Chagas cardiomyopathy, in which the pathogen (Trypanosoma cruzi) persists, 29 and possibly the development of CVD in patients with T1DM with decades of poor glycemic control. 2, 3 Further studies are required to determine whether there is a "point of no return" beyond which cardiac autoimmunity is no longer reversible with improved glycemic control.
How could chronic hyperglycemia trigger the breakdown of immune tolerance to the heart in T1DM? We propose 3 major steps ( Figure 5 ). First, previous studies have shown that the immune system is normally 20 B, In both patients with T1DM and patients with type 2 diabetes mellitus (T2DM), chronic hyperglycemia causes subclinical myocardial injury, leading to leakage and exposure of heart muscle proteins, including α-myosin, to the immune system. C, In patients with T1DM with poor glycemic control, the dysregulated adaptive immune system overreacts to myocardial injury, leading to the expansion of proinflammatory CD4 + T cells specific to α-myosin and the development of autoantibodies to MYH6 and other cardiac antigens. This proinflammatory state is associated with elevated levels of the inflammatory marker, high-sensitivity C-reactive protein (hsCRP), and increased risk for accelerated atherosclerosis and CVD events.
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enriched in autoreactive CD4 + T cells specific for cardiac myosin 20 as a result of a lack of a fundamental process called central tolerance, in which the thymus plays a key role in preventing organ-specific autoimmunity by removing (deleting) strongly self-reactive CD4 + T cells from the circulation 41 ( Figure 5A ). The lack of thymic tolerance to α-myosin (MYH6) leads to the enrichment of peripheral blood with CD4 + T cells reactive to α-myosin and places the heart at increased risk for autoimmune attack in the setting of myocardial injury, for example, after MI. 28, 42 Second, chronic hyperglycemia also causes myocardial damage 21, 22, 43 and is associated with leakage of myocardial proteins into the circulation 44 ( Figure 5B ), potentially leading to the exposure of previously sequestered cardiac antigens, including α-myosin, to the immune system. Third, the dysregulated adaptive immune system in individuals with T1DM "overreacts" to hyperglycemia-induced myocardial injury ( Figure 5C ). Although the number and specificity of cardiac AAbs were associated with subsequent CVD in this study, we postulate that this disease process would be driven primarily by CD4 + T cells (which are required for the production of these immunoglobulin G AAbs 20 ). The idea that AAbs, although not primary disease mediators, can be used to predict disease is perhaps best exemplified by extensive studies on T1DM itself. 33, 45 How could the presence of myocardial autoimmunity in these DCCT patients be mechanistically linked to increased risk for atherosclerotic CVD events, 2 seemingly unrelated clinical entities occurring decades apart? As discussed, it is widely accepted that chronic inflammation plays a pivotal role in the pathogenesis of atherosclerosis. 46 Although innate immune mechanisms clearly contribute to this process, emerging data also support an important role of adaptive immune dysregulation, specifically involving dysregulated CD4 + T cells in the pathogenesis of atherosclerosis 13 and acute coronary syndromes. 11 Indeed, autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus are recognized major risk factors for accelerated atherosclerosis. 11 Atherosclerosis has recently been proposed as a T cell-driven process, particularly involving proinflammatory CD4 + T cells that produce interferon-γ, which is proatherogenic in animal models. 12, 13 Our previous studies showed that the presence of multiple cardiac AAbs correlated with increased frequencies of proinflammatory interferon-γ-producing α-myosinspecific CD4 + T cells in peripheral blood, 20, 28 and in the present study, we showed that patients with T1DM in the DCCT HbA 1c ≥9.0% group share similar AAb expression signatures with patients with chronic Chagas cardiomyopathy, which is believed to be mediated by proinflammatory CD4 + T cells reactive to cardiac myosin. 29, 47 It therefore seems plausible that AAb-positive DCCT patients would have also harbored increased frequencies of cardiac myosin-specific proinflammatory T cells in peripheral blood, contributing to an inflammatory state and possibly increasing the risk for CVD (Figure 5C ). In support of this notion, patients with T1DM in our study who tested positive for ≥2 AAbs and were at increased risk for both CAC and CVD events subsequently showed high hsCRP levels. A recent prospective study showed a significant association between elevated levels of T-cell activation markers and the progression of CAC in T1DM. 48 Our study has several unique strengths. First, the 2 DCCT treatment groups achieved markedly different mean HbA 1c levels over a mean period of 6.5 years, 7 providing the opportunity to test an association between hyperglycemia and cardiac autoimmunity. Second, the DCCT primary prevention cohort was ideal for testing the role of hyperglycemia in autoimmunity, because at baseline the participants had a short duration of T1DM and were relatively healthy with no hypertension, hyperlipidemia, or microalbuminuria; in addition, as part of our study design, patients who developed CVD or renal disease during DCCT were excluded. Thus, the role of hyperglycemia in the development of cardiac autoimmunity could be evaluated without potential CVD confounders. Third, our 2 HbA 1c groups were similar in age and were matched for T1DM duration, sex, and HLA class II genotype, so the major difference between the 2 groups was the HbA 1c level. Fourth, the availability of annual serum samples collected over the DCCT, combined with rich DCCT/EDIC clinical data sets, enabled us to establish a time course for AAb appearance and disappearance relative to HbA 1c levels and risk factors for CVD 8 with a follow-up for 3 decades. 25 Fifth, we were able to compare our findings with a well-characterized T2DM cohort 27 with HbA 1c ≥9.0% and ≤7.0%, enabling us to demonstrate that hyperglycemia-associated cardiac autoimmunity is unique to patients with T1DM. Finally, we performed side-by-side cardiac AAb profiling of a deeply phenotyped cohort with chronic Chagas cardiomyopathy, for whom until now conventional methods for cardiac AAb measurement have not been informative, 49 revealing unanticipated parallels between patients with T1DM with very poor glycemic control and patients with a form of chronic myocarditis. 29 However, our results should also be considered in the context of several limitations. First is the small number of CVD events. As discussed, to rigorously test the association between poor glycemic control and cardiac autoimmunity, we restricted analysis to the primary prevention cohort who, at DCCT baseline, were relatively young and had a short duration of T1DM and in whom the subsequent CVD event rate was generally low. 8, 25 Larger-scale studies involving the entire DCCT cohort and more CVD events are required to further establish a relationship between cardiac autoimmunity and long-term CVD outcomes in T1DM. 
Second, because of the limited sample availability at DCCT baseline, especially for the HbA 1c ≥9.0% group, for many of the AAbs, tests were positive from the first observations, and the exact timing of seroconversion could not be established. Third, by design, the DCCT patients analyzed in this report had a marked HbA 1c separation between the 2 groups, so it was not possible to assess the impact relative to milder HbA 1c elevations. Fourth, it was not feasible to measure CD4 + Tcell responses to cardiac myosin in this study because peripheral blood mononuclear cells were not collected during DCCT, but such samples could be obtained at future EDIC follow-up visits. Fifth, the primary CVD outcome of the DCCT/EDIC study was a composite of outcomes associated primarily with atherosclerotic CVD and not those associated with cardiomyopathy; dedicated evaluation of such outcomes (eg, heart failure) was not possible because of the small number of events. Finally, it could be argued that the DCCT cohort is not representative of the general population with T1DM; however, our preliminary data suggested similar associations between poor glycemic control and expression of cardiac AAbs in a contemporary cohort of young adults with T1DM, which formed the rationale for the present studies.
CVD in T2DM and T1DM is often considered the same disease, with the diagnosis and treatment of CVD in T1DM extrapolated from the experience with T2DM. 4 Without knowledge of T1DM-specific CVD mechanisms, it has been challenging to identify biomarkers that are predictive of CVD in T1DM 50 or to develop T1DM-specific therapies for CVD. Our studies, using sensitive and specific AAb detection methods that are the current gold-standard format for AAb detection, 33 suggest that cardiac AAbs could represent an early biomarker of CVD risk specific for T1DM. Further validation of cardiac AAbs as predictive biomarkers of CVD events in T1DM could aid in the identification of patients at highest risk for future CVD outcomes and may ultimately lead to new ways to prevent CVD.
